Search Results Search Sort by RelevanceMost Recent Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 2 Karen Kreiner, MD Physicians are obligated to inform patients involved in a clinical trial that there is a chance of receiving a placebo, which can result in a deterioration of a medical condition. Virtual Mentor. 2004;6(11):484-485. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411. Case and Commentary Nov 2004 Who Is That? Expanding the Clinical Encounter Vijaya Arekapudi, MD Patients need to completely understand the role of any non-medical personnel present during a procedure and have the right to refuse their attendance. Virtual Mentor. 2004;6(11):486-487. doi: 10.1001/virtualmentor.2004.6.11.ccas3-0411. Case and Commentary Jul 2024 When Are “Paraphernalia” Critical Medical Supplies? Adriane M. dela Cruz, MD, PhD, Donald Egan, MD, MPH, Sarah E. Baker, MD, MA, and John Z. Sadler, MD Evidence of harm reduction interventions’ morbidity and mortality benefits is abundant and of high quality. AMA J Ethics. 2024;26(7):E527-533. doi: 10.1001/amajethics.2024.527. Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Current page 5
Case and Commentary Nov 2004 Heads or Tails: Randomized Placebo-Controlled Trials, Commentary 2 Karen Kreiner, MD Physicians are obligated to inform patients involved in a clinical trial that there is a chance of receiving a placebo, which can result in a deterioration of a medical condition. Virtual Mentor. 2004;6(11):484-485. doi: 10.1001/virtualmentor.2004.6.11.ccas2-0411.
Case and Commentary Nov 2004 Who Is That? Expanding the Clinical Encounter Vijaya Arekapudi, MD Patients need to completely understand the role of any non-medical personnel present during a procedure and have the right to refuse their attendance. Virtual Mentor. 2004;6(11):486-487. doi: 10.1001/virtualmentor.2004.6.11.ccas3-0411.
Case and Commentary Jul 2024 When Are “Paraphernalia” Critical Medical Supplies? Adriane M. dela Cruz, MD, PhD, Donald Egan, MD, MPH, Sarah E. Baker, MD, MA, and John Z. Sadler, MD Evidence of harm reduction interventions’ morbidity and mortality benefits is abundant and of high quality. AMA J Ethics. 2024;26(7):E527-533. doi: 10.1001/amajethics.2024.527.